"Hallucinogens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
| Descriptor ID |
D006213
|
| MeSH Number(s) |
D27.505.696.388 D27.505.954.427.700.372
|
| Concept/Terms |
Hallucinogens- Hallucinogens
- Psychotomimetic Agents
- Agents, Psychotomimetic
- Hallucinogenic Agents
- Agents, Hallucinogenic
- Hallucinogenic Substances
- Substances, Hallucinogenic
- Psychedelics
- Psychedelic Agents
- Agents, Psychedelic
- Hallucinogenic Drugs
- Drugs, Hallucinogenic
|
Below are MeSH descriptors whose meaning is more general than "Hallucinogens".
Below are MeSH descriptors whose meaning is more specific than "Hallucinogens".
This graph shows the total number of publications written about "Hallucinogens" by people in this website by year, and whether "Hallucinogens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 5 | 0 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 6 | 0 | 6 |
| 2023 | 4 | 0 | 4 |
| 2024 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hallucinogens" by people in Profiles.
-
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw Open. 2024 Jun 03; 7(6):e2414650.
-
Psychedelics in Medicine: Can Evidence Keep Up With Enthusiasm? Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May; 9(5):460-461.
-
The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli. Eur J Neurosci. 2024 Jun; 59(12):3224-3235.
-
Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine. Neuropsychopharmacology. 2024 Jun; 49(7):1120-1128.
-
MDMA enhances positive affective responses to social feedback. J Psychopharmacol. 2024 03; 38(3):297-304.
-
Microdosing Psychedelics: Current Evidence From Controlled Studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May; 9(5):500-511.
-
Unique effects of sedatives, dissociatives, psychedelics, stimulants, and cannabinoids on episodic memory: A review and reanalysis of acute drug effects on recollection, familiarity, and metamemory. Psychol Rev. 2024 Mar; 131(2):523-562.
-
Greater subjective effects of a low dose of LSD in participants with depressed mood. Neuropsychopharmacology. 2024 Apr; 49(5):774-781.
-
Impaired inhibition after delta-9-tetrahydrocannabinol in women not related to circulating estradiol levels. Pharmacol Biochem Behav. 2023 04; 225:173547.
-
Progress and Puzzles in Psychedelic Therapy. Biol Psychiatry. 2023 02 01; 93(3):210.